Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T61101 | FLT3-IN-13 | ||
FLT3-IN-13 (compound 20) is a highly effective inhibitor targeting both topoisomerase II and FLT3 proteins in leukemic cells. It exhibits potent activity against these targets, with IC50 values of 2.26 μM for both. Moreover, FLT3-IN-13 induces cell cycle arrest at the G2/M phase and promotes apoptosis. Notably, it displays considerable anticytotoxic activity, specifically against leukemia [1]. | |||
T11298 |
FLT3-IN-3
|
FLT | Angiogenesis; Tyrosine Kinase/Adaptors |
FLT3-IN-3 是 FLT3抑制剂,能够抑制 FLT3 WT (IC50:13 nM) 和 FLT3 D835Y (IC50:8 nM) 。 | |||
T79596 |
FLT3-IN-20
|
||
FLT3-IN-20(compound 34f)作为一种高效FLT3抑制剂,对FLT3-D835Y和FLT3-ITD具有强效性,IC50值分别仅为1 nM和4 nM。该化合物在携带FLT3-ITD突变的AML细胞系MV4-11和MOLM-13中展现出显著的抗增殖效果,其中IC50值分别为7 nM和9 nM;对于带有FLT3-ITD-D835Y突变的MOLM-13变体,其IC50值为4 nM。FLT3-IN-20主要用于肿瘤治疗研究领域。 | |||
T70779 |
BPR1J-340
|
||
BPR1J-340 is a potent and selective FLT3 inhibitor with potential anticancer activity. BPR1J-340 was identified as a novel potent FLT3 inhibitor by biochemical kinase activity (IC50 approximately 25 nM) and cellular proliferation (GC50 approximately 5 nM) assays. BPR1J-340 inhibited the phosphorylation of FLT3 and STAT5 and triggered apoptosis in FLT3-ITD(+) AML cells. The pharmacokinetic parameters of BPR1J-340 in rats were determined. BPR1J-340 also demonstrated pronounced tumor growth inhibit... | |||
T61005 |
K783-0308
|
||
K783-0308 是有效的、选择性的MNK2和FLT3的双重抑制剂,IC50值分别为 406 和 680nM。 K783-0308 促进急性髓性白血病 (AML)的 细胞凋亡和细胞周期停滞在 G0/G1 期。K783-0308 抑制 MV-4-11 和 MOLM-13 细胞生长,IC50 值分别为 10.4 和 10.5 μM |